论文部分内容阅读
目的探讨粗针穿刺活检及新辅助化疗对于乳腺肿瘤ER/PR/PS2/HER-2免疫组化结果的影响。方法乳腺粗针穿刺活检,病理诊断为乳腺癌并UICC分期,所有患者采用CEF或TE方案化疗,分别接受了2个周期及3～4周期的新辅助化疗。同时将穿刺的组织行ER、PR、PS2和HER-2免疫组化的测定,进行对比分析。结果新辅助化疗FAC或TE两种不同化疗方法治疗48例乳腺癌,FAC法化疗26例,占54.2%,TE法化疗22例,占45.8%。乳腺癌新辅助化疗前、后乳腺粗针穿刺活检,免疫组化检测结果ER/PR/PS2/HER-2阳性率无明显增加。结论新辅助化疗对乳腺癌粗针穿刺活检免疫组化ER/PR/PS2/HER-2的表达无显著影响。
Objective To investigate the effect of microneedle needle biopsy and neoadjuvant chemotherapy on the immunohistochemical results of ER / PR / PS2 / HER-2 in breast tumors. Methods The gross needle biopsy of breast was performed. The pathological diagnosis was breast cancer with UICC staging. All patients underwent CEF or TE regimen chemotherapy and accepted two cycles and three to four cycles of neoadjuvant chemotherapy respectively. At the same time the puncture of the organization line ER, PR, PS2 and HER-2 immunohistochemistry determination, comparative analysis. Results Neoadjuvant chemotherapy FAC or TE two different chemotherapy treatment of 48 cases of breast cancer, FAC chemotherapy in 26 cases, accounting for 54.2%, TE law chemotherapy in 22 cases, accounting for 45.8%. There was no significant increase in positive rate of ER / PR / PS2 / HER-2 by immunohistochemistry before and after neoadjuvant chemotherapy for breast cancer. Conclusion Neoadjuvant chemotherapy has no significant effect on the expression of ER / PR / PS2 / HER-2 in primary needle biopsy of breast cancer.